Search research articles
Contact Us
Filters
Showing results (41-50 of 71) with videos related to
Page
of 8
Sort By:
Autoimmunity Reviews
|
December 16, 2019
Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review
Anne Laure Roupie, Hubert de Boysson, Sara Thietart, et al.
The Lancet. Haematology
|
May 28, 2023
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study
Pierre Peterlin, Yannick Le Bris, Pascal Turlure, et al.
Blood Advances
|
February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
Edmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
The Lancet. Haematology
|
January 15, 2018
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Rami Komrokji, Guillermo Garcia-Manero, Lionel Ades, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2013
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis
John Koreth, Joseph Pidala, Waleska S Perez, et al.
British Journal of Haematology
|
June 21, 2021
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study
Thibault Comont, Mathieu Meunier, Amina Cherait, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2021
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
Thomas Cluzeau, Marie Sebert, Ramy Rahmé, et al.
Autoimmunity Reviews
|
July 15, 2017
Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients
Arsene Mekinian, Guillaume Dervin, Nathanael Lapidus, et al.
Blood Advances
|
October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
Thomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
American Journal of Hematology
|
December 31, 2013
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients
Sylvain Thépot, Raphael Itzykson, Valerie Seegers, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 71) with videos related to
Sort By:
Page
of 8
Autoimmunity Reviews
|
December 16, 2019
Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review
Anne Laure Roupie, Hubert de Boysson, Sara Thietart, et al.
The Lancet. Haematology
|
May 28, 2023
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study
Pierre Peterlin, Yannick Le Bris, Pascal Turlure, et al.
Blood Advances
|
February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
Edmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
The Lancet. Haematology
|
January 15, 2018
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Rami Komrokji, Guillermo Garcia-Manero, Lionel Ades, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2013
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis
John Koreth, Joseph Pidala, Waleska S Perez, et al.
British Journal of Haematology
|
June 21, 2021
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study
Thibault Comont, Mathieu Meunier, Amina Cherait, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2021
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
Thomas Cluzeau, Marie Sebert, Ramy Rahmé, et al.
Autoimmunity Reviews
|
July 15, 2017
Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients
Arsene Mekinian, Guillaume Dervin, Nathanael Lapidus, et al.
Blood Advances
|
October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
Thomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
American Journal of Hematology
|
December 31, 2013
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients
Sylvain Thépot, Raphael Itzykson, Valerie Seegers, et al.
Page
of 8